Alexander Beliaev

USPTO Granted Patents = 15 (Patent Applications = 10)

CIPO Patents = 6 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 10)

Average Co-Inventor Count = 3.8

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Mindelo - Vila do Conde, PT (2006 - 2007)
Vila do Conde, PT (2013)
Mindelo, PT (2012 - 2017)
S. Mamede do Coronado, PT (2014 - 2021)
São Mamede do Coronado, PT (2016 - 2022)

Company Filing History:

12 out of 52

Bial-portela Ca & S.a.

Bial-portela & Cª, S.a.

patents

Years Active: 2006-2022

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11434242 - Dopamine-b-hydroxylase inhibitors (2022-09-06),

2. 11034695 - Dopamine-β-hydroxylase inhibitors (2021-06-15),

3. 10975083 - Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors (2021-04-13),

4. 10059696 - Process for preparing 1,3-dihydroimidazole-2-thione derivatives (2018-08-28),

5. 9630951 - 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase (2017-04-25),

6. 9353082 - Pharmaceutical compounds (2016-05-31),

7. 9346751 - Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives (2016-05-24),

8. 8957222 - Process for preparing intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation (2015-02-17),

9. 8865913 - Crystalline forms and processes for their preparation (2014-10-21),

10. 8710239 - Process for preparing synthetic intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation (2014-04-29),

11. 8546571 - Catalytic hydrogenation of ene-carbamates (2013-10-01),

12. 8481582 - 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase (2013-07-09),

13. 8158666 - Process for the preparation of (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-YL)-1,3-dihydroimidazole-2-thione (2012-04-17),

14. 7259271 - Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation (2007-08-21),

15. 7125904 - Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation (2006-10-24),

Title: Alexander Beliaev - Pioneering Inventor in Dopamine-b-hydroxylase Inhibitors

Introduction: Alexander Beliaev, a prolific inventor hailing from S. Mamede do Coronado, Portugal, is known for his groundbreaking work in the field of dopamine-b-hydroxylase inhibitors. With an impressive portfolio of 15 patents, Beliaev has made significant contributions to the pharmaceutical industry.

Latest Patents: One of Beliaev's latest patents revolves around dopamine-β-hydroxylase inhibitors. This invention encompasses compounds, pharmaceutical compositions, therapeutic methods, and processes related to dopamine-b-hydroxylase inhibition. These innovations hold immense potential in the realm of therapy and drug development.

Career Highlights: Beliaev has garnered experience working with esteemed companies such as Bial-Portela & Ca S.A. His tenure at these organizations has been marked by a dedication to pushing the boundaries of pharmaceutical research and development. Beliaev's commitment to innovation has propelled him to the forefront of the industry.

Collaborations: Throughout his career, Beliaev has collaborated with accomplished professionals in the field, including David Alexander Learmonth and Laszlo Erno Kiss. These collaborations have fostered a dynamic exchange of ideas, leading to further advancements in the domain of dopamine-b-hydroxylase inhibitors.

Conclusion: Alexander Beliaev's relentless pursuit of innovation has shaped the landscape of pharmaceuticals, particularly in the realm of dopamine-b-hydroxylase inhibitors. His impactful contributions underscore his status as a trailblazer in the field, with patents that stand as a testament to his ingenuity and expertise.

This text is generated by artificial intelligence and may not be accurate.